Name (Synonyms) | Correlation | |
---|---|---|
drug2795 | T89 Wiki | 1.00 |
drug2677 | Standard Care Wiki | 0.50 |
There is one clinical trial.
The purpose of this study is to assess whether lopinavir/ritonavir (or eventually other antiviral drugs) is effective at reducing the rate of hospitalization among confirmed COVID-19 cases treated as outpatients.
Description: Hospitalization associated with desaturation (SpO2 ≤92%) or death due to any cause
Measure: Hospitalization or death Time: 15 days following randomizationDescription: Death due to any cause
Measure: All-cause mortality Time: 15 days following randomizationDescription: Death due to any cause
Measure: All-cause mortality Time: 28 days following randomizationDescription: Length of time between randomization and hospitalization associated with desaturation (SpO2 ≤92%)
Measure: Time to hospitalization Time: 28 days following randomizationDescription: Total duration of hospitalization associated with desaturation (SpO2 ≤92%)
Measure: Length of hospitalization Time: 28 days following randomizationDescription: Proportion of participants admitted to an intensive care unit
Measure: Admission to intensive care Time: 28 days following randomizationDescription: Proportion of participants having an adverse event
Measure: Adverse events Time: 28 days following randomizationDescription: Proportion of participants having a serious adverse event
Measure: Serious adverse events Time: 28 days following randomization